The value of bendamustine dose and cycles, sIL-2R, and LDH in follicular lymphoma patients treated with bendamustine plus rituximab.

Tatsuro Jo,Masatoshi Matsuo,Jun Taguchi,Kuniko Abe,Kazuto Shigematsu

The value of bendamustine dose and cycles, sIL-2R, and LDH in follicular lymphoma patients treated with bendamustine plus rituximab.

2020

Tatsuro Jo
Masatoshi Matsuo
Jun Taguchi
Kuniko Abe
Kazuto Shigematsu

e20055Background: Bendamustine plus rituximab therapy (BR) is one of the mainstays of therapy for follicular lymphoma (FL) patients (pts). Adverse events such as lymphopenia, neutropenia, and skin ...

Keywords:

Oncology
Internal medicine
Rituximab
Pathology
Bendamustine
Medicine
Follicular lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations